
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7010674/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inflammation in pediatric epilepsies: Update on clinical features and treatment options. Epilepsy and Behavior, 2022, 131, 107959.	1.7	6
2	Hypoxemia increases blood-brain barrier permeability during extreme apnea in humans. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 1120-1135.	4.3	18
3	GFAP and S100B: What You Always Wanted to Know and Never Dared to Ask. Frontiers in Neurology, 2022, 13, 835597.	2.4	25
4	Diagnostic biomarker kinetics: how brain-derived biomarkers distribute through the human body, and how this affects their diagnostic significance: the case of S100B. Fluids and Barriers of the CNS, 2022, 19, 32.	5.0	7
5	Pro- and Anti-inflammatory Neurovascular Processes in Epilepsy: A Fragile and Dynamic Equilibrium. Agents and Actions Supplements, 2021, , 1-20.	0.2	0
6	Editorial: Biomarkers of Brain Damage – A Complex Challenge With Great Potential. Frontiers in Neurology, 2021, 12, 664445.	2.4	3
7	Brain dysfunction in COVIDâ€19 and CARâ€T therapy: cytokine stormâ€associated encephalopathy. Annals of Clinical and Translational Neurology, 2021, 8, 968-979.	3.7	52
8	Akinetic mutism in COVID-19-related encephalopathy: A cytokine-mediated maladaptive sickness behavioral response?. Brain, Behavior, & Immunity - Health, 2021, 15, 100272.	2.5	3
9	Peripheral markers of TBI and bloodâ^'brain barrier disruption. , 2020, , 43-54.		1
10	ls Salivary S100B a Biomarker of Traumatic Brain Injury? A Pilot Study. Frontiers in Neurology, 2020, 11, 528.	2.4	22
11	Peripheral Blood and Salivary Biomarkers of Blood–Brain Barrier Permeability and Neuronal Damage: Clinical and Applied Concepts. Frontiers in Neurology, 2020, 11, 577312.	2.4	36
12	In vitro Models of the Blood–Brain Barrier: Tools in Translational Medicine. Frontiers in Medical Technology, 2020, 2, 623950.	2.5	43
13	Breakdown of blood brain barrier as a mechanism of post-traumatic epilepsy. Neurobiology of Disease, 2019, 123, 20-26.	4.4	50
14	Fundamentals of Brainâ \in "Barrier Anatomy and Global Functions. , 2019, , 3-20.		2
15	Blood–Brain Barrier in Disease States. , 2019, , 21-37.		1
16	Cerebrospinal fluid dynamics and intracranial pressure elevation in neurological diseases. Fluids and Barriers of the CNS, 2019, 16, 9.	5.0	156
17	156. The Impact of Childhood Trauma on the Blood-Brain Barrier and the Risk of Suicide. Biological Psychiatry, 2019, 85, S65.	1.3	1
18	Tau in Chronic Traumatic Encephalopathy. JAMA Neurology, 2018, 75, 381.	9.0	3

#	Article	IF	CITATIONS
19	The role and diagnostic significance of cellular barriers after concussive head trauma. Concussion, 2018, 3, CNC53.	1.0	25
20	The role of brain barriers in fluid movement in the CNS: is there a â€~glymphatic' system?. Acta Neuropathologica, 2018, 135, 387-407.	7.7	429
21	Cerebrovascular heterogeneity and neuronal excitability. Neuroscience Letters, 2018, 667, 75-83.	2.1	28
22	Use of Blood Biomarkers in the Assessment of Sports-Related Concussion—A Systematic Review in the Context of Their Biological Significance. Clinical Journal of Sport Medicine, 2018, 28, 561-571.	1.8	31
23	IFN-γ, IL-17A, or zonulin rapidly increase the permeability of the blood-brain and small intestinal epithelial barriers: Relevance for neuro-inflammatory diseases. Biochemical and Biophysical Research Communications, 2018, 507, 274-279.	2.1	107
24	Biomarkers in traumatic brain injury (TBI): a review. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2989-3000.	2.2	125
25	How do we use inÂvitro models to understand epileptiform and ictal activity? A report of the <scp>TASK</scp> 1â€ <scp>WG</scp> 4 group of the <scp>ILAE</scp> / <scp>AES</scp> Joint Translational Task Force. Epilepsia Open, 2018, 3, 460-473.	2.4	17
26	Modulation of glucocorticoid receptor in human epileptic endothelial cells impacts drug biotransformation in an inÂvitro blood–brain barrier model. Epilepsia, 2018, 59, 2049-2060.	5.1	16
27	Overexpression of pregnane X and glucocorticoid receptors and the regulation of cytochrome P450 in human epileptic brain endothelial cells. Epilepsia, 2017, 58, 576-585.	5.1	45
28	Methodological standards for inÂvitro models of epilepsy and epileptic seizures. A <scp>TASK</scp> 1â€ <scp>WG</scp> 4 report of the <scp>AES</scp> / <scp>ILAE</scp> Translational Task Force of the ILAE. Epilepsia, 2017, 58, 40-52.	5.1	31
29	Detection of brain-directed autoantibodies in the serum of non-small cell lung cancer patients. PLoS ONE, 2017, 12, e0181409.	2.5	6
30	S100B and S100B autoantibody as biomarkers for early detection of brain metastases in lung cancer. Translational Lung Cancer Research, 2016, 5, 413-419.	2.8	23
31	Improving the clinical management of traumatic brain injury through the pharmacokinetic modeling of peripheral blood biomarkers. Fluids and Barriers of the CNS, 2016, 13, 21.	5.0	40
32	<scp>WONOEP</scp> appraisal: Molecular and cellular biomarkers for epilepsy. Epilepsia, 2016, 57, 1354-1362.	5.1	81
33	Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction. Clinical Rheumatology, 2016, 35, 2989-2997.	2.2	17
34	Pathophysiological implications of neurovascular P450 in brain disorders. Drug Discovery Today, 2016, 21, 1609-1619.	6.4	46
35	Lack of CAR impacts neuronal function and cerebrovascular integrity in vivo. Experimental Neurology, 2016, 283, 39-48.	4.1	14
36	Is phosphorylated tau unique to chronic traumatic encephalopathy? Phosphorylated tau in epileptic brain and chronic traumatic encephalopathy. Brain Research, 2016, 1630, 225-240.	2.2	120

#	Article	IF	CITATIONS
37	Blood–brain barrier, bulk flow, and interstitial clearance in epilepsy. Journal of Neuroscience Methods, 2016, 260, 118-124.	2.5	58
38	Cerebral Waste Accumulation and Glymphatic Clearance as Mechanisms of Human Neurological Diseases. Journal of Neurology and Neuromedicine, 2016, 1, 15-19.	0.9	17
39	S100B blood levels and childhood trauma in adolescent inpatients. Journal of Psychiatric Research, 2015, 62, 14-22.	3.1	31
40	Sertralineâ€induced potentiation of the CYP3A4â€dependent neurotoxicity of carbamazepine: An in vitro study. Epilepsia, 2015, 56, 439-449.	5.1	23
41	SEMA4D compromises blood–brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiology of Disease, 2015, 73, 254-268.	4.4	84
42	Levels of S100B in brain and blood of rats with diabetic ketoacidosis. Brain Research, 2015, 1624, 536-544.	2.2	5
43	Does Systemic Inflammation Play a Role in Pediatric Psychosis?. Clinical Schizophrenia and Related Psychoses, 2015, 9, 65-78B.	1.4	36
44	Persistent, Long-term Cerebral White Matter Changes after Sports-Related Repetitive Head Impacts. PLoS ONE, 2014, 9, e94734.	2.5	230
45	Is Peripheral Immunity Regulated by Blood-Brain Barrier Permeability Changes?. PLoS ONE, 2014, 9, e101477.	2.5	38
46	Effect of status epilepticus and antiepileptic drugs on CYP2E1 brain expression. Neuroscience, 2014, 281, 124-134.	2.3	22
47	What Non-neuronal Mechanisms Should Be Studied to Understand Epileptic Seizures?. Advances in Experimental Medicine and Biology, 2014, 813, 253-264.	1.6	15
48	ILâ€1β associations with posttraumatic epilepsy development: A genetics and biomarker cohort study. Epilepsia, 2014, 55, 1313-1313.	5.1	5
49	Inflammatory pathways of seizure disorders. Trends in Neurosciences, 2014, 37, 55-65.	8.6	196
50	Mechanisms of Cerebral Edema Leading to Early Seizures After Traumatic Brain Injury. , 2014, , 29-45.		10
51	Significance of Ubiquitin Carboxy-Terminal Hydrolase L1 Elevations in Athletes after Sub-Concussive Head Hits. PLoS ONE, 2014, 9, e96296.	2.5	72
52	A new dynamic in vitro modular capillaries-venules modular system: Cerebrovascular physiology in a box. BMC Neuroscience, 2013, 14, 18.	1.9	89
53	A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches. Epilepsia, 2013, 54, 30-32.	5.1	51
54	Intracellular and circulating neuronal antinuclear antibodies in human epilepsy. Neurobiology of Disease, 2013, 59, 206-219.	4.4	18

#	Article	IF	CITATIONS
55	New immunological approaches in treating and diagnosing CNS diseases. Pharmaceutical Patent Analyst, 2013, 2, 361-371.	1.1	1
56	Expression and functional relevance of <scp>UGT</scp> 1 <scp>A</scp> 4 in a cohort of human drugâ€resistant epileptic brains. Epilepsia, 2013, 54, 1562-1570.	5.1	37
57	S100B as a Serum Marker for Early Detection of Brain Metastasis in Lung Cancer. Chest, 2013, 144, 644A.	0.8	1
58	Consequences of Repeated Blood-Brain Barrier Disruption in Football Players. PLoS ONE, 2013, 8, e56805.	2.5	246
59	The blood-brain barrier hypothesis in drug resistant epilepsy. Brain, 2012, 135, e211-e211.	7.6	22
60	Inflammatory events at blood–brain barrier in neuroinflammatory and neurodegenerative disorders: Implications for clinical disease. Epilepsia, 2012, 53, 45-52.	5.1	97
61	Blood–brain barrier dysfunction and epilepsy: Pathophysiologic role and therapeutic approaches. Epilepsia, 2012, 53, 1877-1886.	5.1	199
62	Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents. Advanced Drug Delivery Reviews, 2012, 64, 605-613.	13.7	87
63	Are you in or out? Leukocyte, ion, and neurotransmitter permeability across the epileptic blood–brain barrier. Epilepsia, 2012, 53, 26-34.	5.1	111
64	A pro-convulsive carbamazepine metabolite: Quinolinic acid in drug resistant epileptic human brain. Neurobiology of Disease, 2012, 46, 692-700.	4.4	20
65	Serum S100B in patients with and without delirium. Neurology Psychiatry and Brain Research, 2012, 18, 53.	2.0	0
66	Patients with generalised epilepsy have a higher white blood cell count than patients with focal epilepsy. Epileptic Disorders, 2012, 14, 57-63.	1.3	16
67	Efficacy of Anti-Inflammatory Therapy in a Model of Acute Seizures and in a Population of Pediatric Drug Resistant Epileptics. PLoS ONE, 2011, 6, e18200.	2.5	130
68	Cellular localization and functional significance of CYP3A4 in the human epileptic brain. Epilepsia, 2011, 52, 562-571.	5.1	70
69	Modulation of peripheral cytotoxic cells and ictogenesis in a model of seizures. Epilepsia, 2011, 52, 1627-1634.	5.1	61
70	Engaging neuroscience to advance translational research in brain barrier biology. Nature Reviews Neuroscience, 2011, 12, 169-182.	10.2	508
71	A Dynamic <i>in vitro</i> BBB Model for the Study of Immune Cell Trafficking into the Central Nervous System. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 767-777.	4.3	119
72	Transbuccal Delivery of CNS Therapeutic Nanoparticles: Synthesis, Characterization, and In Vitro Permeation Studies. ACS Chemical Neuroscience, 2011, 2, 676-683.	3.5	38

#	Article	IF	CITATIONS
73	The role of shear stress in Blood-Brain Barrier endothelial physiology. BMC Neuroscience, 2011, 12, 40.	1.9	325
74	The Etiological Role of Blood-Brain Barrier Dysfunction in Seizure Disorders. Cardiovascular Psychiatry and Neurology, 2011, 2011, 1-9.	0.8	58
75	Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases. Current Drug Metabolism, 2011, 12, 742-749.	1.2	65
76	Multimodal investigations of trans-endothelial cell trafficking under condition of disrupted blood-brain barrier integrity. BMC Neuroscience, 2010, 11, 34.	1.9	21
77	Blood–brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity. Brain Research, 2010, 1353, 176-186.	2.2	98
78	Not Again! the Role of Blood–Brain Barrier Failure in Epileptogenesis: Amolecular Update. Epilepsy Currents, 2010, 10, 67-69.	0.8	3
79	Pattern of P450 expression at the human blood–brain barrier: Roles of epileptic condition and laminar flow. Epilepsia, 2010, 51, 1408-1417.	5.1	96
80	Transporters in Drug-Refractory Epilepsy: Clinical Significance. Clinical Pharmacology and Therapeutics, 2010, 87, 13-15.	4.7	35
81	Pathophysiological Impact of Cigarette Smoke Exposure on the Cerebrovascular System with a Focus on the Blood-brain Barrier: Expanding the Awareness of Smoking Toxicity in an Underappreciated Area. International Journal of Environmental Research and Public Health, 2010, 7, 4111-4126.	2.6	139
82	Extracranial Sources of S100B Do Not Affect Serum Levels. PLoS ONE, 2010, 5, e12691.	2.5	95
83	Factors Modulating Seizure Susceptibility. , 2010, , 193-201.		0
84	Serum S100B: A Potential Biomarker for Suicidality in Adolescents?. PLoS ONE, 2010, 5, e11089.	2.5	67
85	Suicidal Behavior in Adolescents with First-Episode Psychosis. Clinical Schizophrenia and Related Psychoses, 2010, 4, 34-40.	1.4	24
86	Blood–Brain Barrier, Blood Flow, Neoplasms and Epilespy. , 2010, , 21-34.		0
87	Small Vessel Ischemic Disease of the Brain and Brain Metastases in Lung Cancer Patients. PLoS ONE, 2009, 4, e7242.	2.5	17
88	Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiology of Disease, 2009, 33, 171-181.	4.4	270
89	Matrix metalloproteinase-7 facilitates immune access to the CNS in experimental autoimmune encephalomyelitis. BMC Neuroscience, 2009, 10, 17.	1.9	49
90	Bone marrow-derived cells are the major source of MMP-9 contributing to blood–brain barrier dysfunction and infarct formation after ischemic stroke in mice. Brain Research, 2009, 1294, 183-192.	2.2	59

#	Article	IF	CITATIONS
91	Blood–brain barrier damage and brain penetration of antiepileptic drugs: Role of serum proteins and brain edema. Epilepsia, 2009, 50, 664-677.	5.1	81
92	Management of the patient with medically refractory epilepsy. Expert Review of Neurotherapeutics, 2009, 9, 1791-1802.	2.8	72
93	Immortalized Human Brain Endothelial Cells and Flow-Based Vascular Modeling: A Marriage of Convenience for Rational Neurovascular Studies. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 312-328.	4.3	230
94	Drug Resistance in Epilepsy: The Role of the Blood-Brain Barrier. Novartis Foundation Symposium, 2008, , 38-53.	1.1	67
95	Development of a Humanized In Vitro Blood?Brain Barrier Model to Screen for Brain Penetration of Antiepileptic Drugs. Epilepsia, 2007, 48, 505-516.	5.1	147
96	Seizure-Promoting Effect of Blood?Brain Barrier Disruption. Epilepsia, 2007, 48, 732-742.	5.1	442
97	RLIP76 in AED drug resistance. Epilepsia, 2007, 48, 1218-1219.	5.1	8
98	In Vivo and In Vitro Effects of Pilocarpine: Relevance to Ictogenesis. Epilepsia, 2007, 48, 1934-1946.	5.1	151
99	Dissociation between <i>in vitro</i> and <i>in vivo</i> epileptogenicity in a rat model of cortical dysplasia. Epileptic Disorders, 2007, 9, 11-19.	1.3	27
100	Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics. Recent Patents on CNS Drug Discovery, 2006, 1, 157-173.	0.9	10
101	The Blood?Brain Barrier and Epilepsy. Epilepsia, 2006, 47, 1761-1774.	5.1	352
102	In vitro responsiveness of human-drug-resistant tissue to antiepileptic drugs: Insights into the mechanisms of pharmacoresistance. Brain Research, 2006, 1086, 201-213.	2.2	20
103	Side by side comparison between dynamic versus static models of blood–brain barrier in vitro: A permeability study. Brain Research, 2006, 1109, 1-13.	2.2	177
104	Alternating current electrical stimulation enhanced chemotherapy: a novel strategy to bypass multidrug resistance in tumor cells. BMC Cancer, 2006, 6, 72.	2.6	42
105	Loss of shear stress induces leukocyte-mediated cytokine release and blood-brain barrier failure in dynamic in vitro blood-brain barrier model. Journal of Cellular Physiology, 2006, 206, 68-77.	4.1	61
106	A Pilot Study on Brain-to-Plasma Partition of 10,11-Dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 Brain Expression in Epilepsy Patients Not Responding to Oxcarbazepine. Epilepsia, 2005, 46, 1613-1619.	5.1	86
107	The NMDA receptor NR2B subunit contributes to epileptogenesis in human cortical dysplasia. Brain Research, 2005, 1046, 10-23.	2.2	84
108	S100β as a predictor of brain metastases. Cancer, 2005, 104, 817-824.	4.1	59

#	Article	IF	CITATIONS
109	RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neuroscience, 2005, 6, 61.	1.9	74
110	Drug delivery and in vitro models of the blood-brain barrier. Current Opinion in Drug Discovery & Development, 2005, 8, 89-99.	1.9	27
111	Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Medicine, 2004, 2, 37.	5.5	128
112	Glycerophosphoinositol and dexamethasone improve transendothelial electrical resistance in an in vitro study of the blood–brain barrier. Brain Research, 2004, 997, 147-151.	2.2	42
113	Peripheral markers of blood–brain barrier damage. Clinica Chimica Acta, 2004, 342, 1-12.	1.1	207
114	Peripheral detection of S100β during cardiothoracic surgery: what are we really measuring?. Annals of Thoracic Surgery, 2004, 78, 46-52.	1.3	65
115	Use of a three-dimensional in vitro model of the rat blood–brain barrier to assay nucleoside efflux from brain. Brain Research, 2003, 980, 233-241.	2.2	42
116	Serum S100β. Cancer, 2003, 97, 2806-2813.	4.1	249
117	Vascular and Parenchymal Mechanisms in Multiple Drug Resistance: a Lesson from Human Epilepsy. Current Drug Targets, 2003, 4, 297-304.	2.1	75
118	Serum Transthyretin Monomer as a Possible Marker of Blood-to-CSF Barrier Disruption. Journal of Neuroscience, 2003, 23, 1949-1955.	3.6	87
119	Peripheral markers of brain damage and blood-brain barrier dysfunction. Restorative Neurology and Neuroscience, 2003, 21, 109-21.	0.7	163
120	Mechanisms of Endothelial Survival Under Shear Stress. Endothelium: Journal of Endothelial Cell Research, 2002, 9, 89-102.	1.7	74
121	A new dynamic in vitro model for the multidimensional study of astrocyte–endothelial cell interactions at the blood–brain barrier. Brain Research, 2002, 951, 243-254.	2.2	155
122	Insulin permeability across an in vitro dynamic model of endothelium. Pharmaceutical Research, 2002, 19, 445-450.	3.5	20
123	Persistent SIV infection of a blood-brain barrier model. Journal of NeuroVirology, 2002, 8, 270-280.	2.1	12
124	Drug resistance in epilepsy: the role of the blood-brain barrier. Novartis Foundation Symposium, 2002, 243, 38-47; discussion 47-53, 180-5.	1.1	29
125	Overexpression of Multiple Drug Resistance Genes in Endothelial Cells from Patients with Refractory Epilepsy. Epilepsia, 2001, 42, 1501-1506.	5.1	409
126	Blood-brain barrier preservation in the in vitro isolated guinea pig brain preparation. Journal of Neuroscience Research, 2001, 66, 289-297.	2.9	33

DAMIR JANIGRO

#	Article	IF	CITATIONS
127	Mechanisms of glucose transport at the blood–brain barrier: an in vitro study. Brain Research, 2001, 904, 20-30.	2.2	140
128	Regional variation in brain capillary density and vascular response to ischemia. Brain Research, 2001, 910, 81-93.	2.2	230
129	Blood–brain barrier, ion homeostasis and epilepsy: possible implications towards the understanding of ketogenic diet mechanisms. Epilepsy Research, 1999, 37, 223-232.	1.6	111
130	Dynamic in vitro modeling of the blood–brain barrier: a novel tool for studies of drug delivery to the brain. Pharmaceutical Science & Technology Today, 1999, 2, 7-12.	0.7	47
131	A new model of the blood–brain barrier. NeuroReport, 1999, 10, 3725-3731.	1.2	75
132	Impaired K ⁺ Homeostasis and Altered Electrophysiological Properties of Post-Traumatic Hippocampal Glia. Journal of Neuroscience, 1999, 19, 8152-8162.	3.6	212
133	Selective loss of hippocampal long-term potentiation, but not depression, following fluid percussion injury. Brain Research, 1998, 786, 64-79.	2.2	123
134	Functional Specialization and Topographic Segregation of Hippocampal Astrocytes. Journal of Neuroscience, 1998, 18, 4425-4438.	3.6	212
135	Understanding the Physiology of the Blood-Brain Barrier: In Vitro Models. Physiology, 1998, 13, 287-293.	3.1	40
136	Reduction of K ⁺ Uptake in Glia Prevents Long-Term Depression Maintenance and Causes Epileptiform Activity. Journal of Neuroscience, 1997, 17, 2813-2824.	3.6	155
137	Heterogeneity of Astrocyte Resting Membrane Potentials and Intercellular Coupling Revealed by Whole-Cell and Gramicidin-Perforated Patch Recordings from Cultured Neocortical and Hippocampal Slice Astrocytes. Journal of Neuroscience, 1997, 17, 6850-6863.	3.6	135
138	Morphological and functional characterization of an in vitro blood–brain barrier model. Brain Research, 1997, 771, 329-342.	2.2	158